Health care stocks were edging higher premarket Wednesday as the iShares Biotechnology ETF (IBB) was 0.4% higher and the Health Care Select Sector SPDR Fund (XLV) was recently up 0.5%.

Argenx (ARGX) shares were up more than 2% after the company said it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.

SAGE Therapeutics (SAGE) shares were down over 5% after the company said its phase 2 DIMENSION study of dalzanemdor in participants with cognitive impairment associated with Huntington's Disease did not meet its primary and secondary endpoints.

Novo Nordisk (NVO) has rolled out Wegovy in China to treat adults with obesity and

overweight, a company spokesperson confirmed to MT Newswires in an email. Novo Nordisk shares were up over 1% premarket.